Management of Pravastatin and Bezafibrate Combination Therapy

Introduction to Combination Therapy

The American College of Cardiology recommends starting with pravastatin 20 mg once daily, which is the standard initial dose, and evaluating lipid response at 6-8 weeks before considering dose increase 1
The American College of Cardiology suggests that if LDL-C goals are not achieved, the dose of pravastatin should be increased to 40 mg daily, while maintaining bezafibrate at 200 mg daily 1
The FDA-approved maximum dose of pravastatin is 80 mg daily, but in combination therapy with fibrates, it is recommended to use caution and limit to moderate doses 1, 2

The American College of Cardiology recommends evaluating lipid profile at 6-8 weeks after initiating therapy and adjusting the dose of pravastatin as needed, with a maximum dose of 40 mg daily in combination therapy 1
The American College of Cardiology suggests that pravastatin has the advantage of not being metabolized by CYP3A4, reducing pharmacological interactions compared to other statins, but still requires caution when combined with bezafibrate 1

The American College of Cardiology recommends maintaining bezafibrate at 200 mg daily when used in combination with statins to reduce the risk of myopathy, and avoiding the maximum dose of 400 mg 1
The American Academy of Family Physicians suggests that if triglycerides remain elevated (>200 mg/dL), consideration should be given to optimizing glucose control and diet before increasing bezafibrate 3

The American College of Cardiology recommends monitoring CPK only when muscle symptoms are present, and not as a routine measure 1
The American College of Cardiology suggests evaluating ALT/AST at 12 weeks after each dose change, and then annually 1
The American College of Cardiology recommends monitoring for muscle symptoms at each visit, and measuring CPK only if symptoms are present 1

The American College of Cardiology recommends using minimum effective doses in elderly patients, especially frail women, and considering monotherapy in patients with multisystem disease 1
The American Academy of Family Physicians suggests that patients with creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) have a relative contraindication for combination therapy 3

The American College of Cardiology recommends suspending bezafibrate and continuing with pravastatin alone, increasing the dose to 40-80 mg as tolerated, if myopathy or intolerance develops 1
The American College of Cardiology suggests considering adding ezetimibe 10 mg to the statin as a safer alternative to combination statin-fibrate therapy 2